Nontoxic combretafuranone analogues with high in vitro antibacterial activity.

[1]  E. Pelkey,et al.  Synthesis and evaluation of the anti-proliferative activity of diaryl-3-pyrrolin-2-ones and fused analogs. , 2017, Bioorganic & medicinal chemistry letters.

[2]  Wei Li,et al.  Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site. , 2016, Anti-cancer agents in medicinal chemistry.

[3]  B. Monk,et al.  Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Apostolova,et al.  Combretastatin A-4 analogues with benzoxazolone scaffold: Synthesis, structure and biological activity. , 2016, European journal of medicinal chemistry.

[5]  G. Cholewiński,et al.  Synthesis of Combretastatin A-4 Analogs and their Biological Activities. , 2016, Anti-cancer agents in medicinal chemistry.

[6]  Gurneet Kaur,et al.  Recent developments in tubulin polymerization inhibitors: An overview. , 2014, European journal of medicinal chemistry.

[7]  Chunjian Liu,et al.  Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4. , 2014, European journal of medicinal chemistry.

[8]  M. J. Uddin,et al.  Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. , 2014, ACS Medicinal Chemistry Letters.

[9]  Jim Euchner Design , 2014, Catalysis from A to Z.

[10]  Madhusoodanan Mottamal,et al.  Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents , 2014, Journal of medicinal chemistry.

[11]  D. V. Tsyganov,et al.  3-(5-)-Amino-o-diarylisoxazoles: regioselective synthesis and antitubulin activity. , 2014, European journal of medicinal chemistry.

[12]  K. Behnia,et al.  Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties. , 2013, Journal of medicinal chemistry.

[13]  Duane D. Miller,et al.  An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.

[14]  D. Newman,et al.  Anticancer Agents from Natural Products, Second Edition , 2011 .

[15]  S. Remick,et al.  Combretastatin A4 phosphate: a novel vascular disrupting agent. , 2010, Future oncology.

[16]  Giovanni Sorba,et al.  Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.

[17]  D. Kingston,et al.  Anticancer Agents from Natural Products , 2005 .

[18]  N. Nam Combretastatin A-4 analogues as antimitotic antitumor agents. , 2003, Current medicinal chemistry.

[19]  E. Hamel,et al.  One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. , 2002, Journal of medicinal chemistry.

[20]  N. Nam,et al.  Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. , 2002, Bioorganic & medicinal chemistry letters.

[21]  P. Koudelka,et al.  3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones: synthesis and biological activity of a novel group of potential antifungal drugs. , 2001, Journal of medicinal chemistry.

[22]  M. Boyd,et al.  Antineoplastic agents 442. Synthesis and biological activities of dioxostatin. , 2000, Anti-cancer drug design.

[23]  G. Pettit,et al.  Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. , 1998, Anti-cancer drug design.

[24]  M. Cushman,et al.  Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. , 1992, Journal of medicinal chemistry.

[25]  P. Prasit,et al.  Synthesis of Rofecoxib, (MK 0966, Vioxx® 4-(4′-Methylsulfonylphenyl)-3-Phenyl-2(5H)-Furanone), a Selective and Orally Active Inhibitor of Cyclooxygenase-2 , 2001 .